If their phase I clinical trial to test the safety and preliminary efficacy of this therapy gains approval, University of Pittsburgh researchers will test the therapy on 10 patients who suffer from
chronic ischemic stroke — the most common form, in which clots block blood flow.
Dr. Paul R. Sanberg, Distinguished University Professor, a co-author of the paper, concluded that «these novel data showing BSCB damage in subacute and
chronic ischemic stroke may lead to development of new therapeutic approaches for patients with ischemic cerebral infarction.»
Not exact matches
Ischemic heart disease tops the list, followed, in order, by trachea, bronchus and lung cancers;
stroke;
chronic obstructive pulmonary disease; road injuries; suicide; and diabetes.
«This study, carried out using laboratory rats modeling
stroke, demonstrated that
ischemic stroke — in both its subacute and
chronic stages — damages the BSCB in a variety of ways, creating a toxic environment in the spinal cord that can lead to further disability and exacerbate disease pathology,» said study lead author Dr. Svitlana Garbuzova - Davis, associate professor in USF's Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair.
The researchers focused on specific cardiovascular disease diagnoses: myocardial infarction (heart attack),
chronic heart failure,
stroke, and
ischemic heart disease.
Diabetes or elevated blood sugar; Cancer (excluding basal cell or squamous cell carcinoma of the skin);
stroke, transient
ischemic attack (TIA or mini-
stroke); emphysema;
chronic bronchitis or
chronic lung disease; major depression or anxiety that required psychiatric treatment; bipolar disease or mood disorder; schizophrenia.
stroke, transient
ischemic attack (TIA or mini-
stroke); emphysema;
chronic bronchitis or
chronic lung disease;